Related Experiment Videos
Bisphosphonates: new indications and methods of administration
1Department of Medicine, University of Auckland, New Zealand. i.reid@auckland.ac.nz
Current Opinion in Rheumatology
|June 24, 2003
Summary
New studies confirm bisphosphonate drugs effectively prevent fractures in osteoporosis patients. Intermittent dosing, like yearly zoledronate, shows promise for improved convenience and compliance.
Area of Science:
- Pharmacology
- Bone Metabolism
- Oncology
Background:
- Bisphosphonates are established treatments for osteoporosis.
- Long-term efficacy and administration schedules are key considerations for patient adherence.
Purpose of the Study:
- To review the latest evidence on bisphosphonate efficacy in fracture prevention.
- To explore the potential for intermittent bisphosphonate administration.
- To examine bisphosphonate applications beyond osteoporosis.
Main Methods:
- Review of studies published in 2002 concerning bisphosphonate therapy.
- Analysis of data on bone density, bone turnover markers, and skeletal complications.
- Evaluation of bisphosphonate roles in various bone-related conditions.
Main Results:
- Bisphosphonates demonstrate efficacy in preventing osteoporotic fractures.
- Zoledronate, a potent bisphosphonate, shows comparable bone density and turnover marker changes with annual dosing.
- Evidence supports bisphosphonates in preventing skeletal complications of malignancy and potentially reducing breast cancer mortality.
- Confirmed roles in osteogenesis imperfecta and suggested roles in ankylosing spondylitis, myelofibrosis, and hypertrophic pulmonary osteoarthropathy.
Conclusions:
- Intermittent bisphosphonate regimens, if proven effective for fracture prevention, may increase patient compliance.
- Bisphosphonates have expanding therapeutic applications in skeletal-related complications and other bone disorders.